MA40682B1 - Anticorps anti-ox40 et procédés d'utilisation correspondants - Google Patents
Anticorps anti-ox40 et procédés d'utilisation correspondantsInfo
- Publication number
- MA40682B1 MA40682B1 MA40682A MA40682A MA40682B1 MA 40682 B1 MA40682 B1 MA 40682B1 MA 40682 A MA40682 A MA 40682A MA 40682 A MA40682 A MA 40682A MA 40682 B1 MA40682 B1 MA 40682B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- methods
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
L'invention concerne des anticorps anti-ox40 et des procédés d'utilisation de ceux-ci.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461973193P | 2014-03-31 | 2014-03-31 | |
US201461989448P | 2014-05-06 | 2014-05-06 | |
US201462073873P | 2014-10-31 | 2014-10-31 | |
US201462080171P | 2014-11-14 | 2014-11-14 | |
PCT/US2015/023432 WO2015153513A1 (fr) | 2014-03-31 | 2015-03-30 | Anticorps anti-ox40 et procédés d'utilisation correspondants |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40682A MA40682A (fr) | 2017-02-08 |
MA40682B1 true MA40682B1 (fr) | 2020-01-31 |
Family
ID=52829446
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40682A MA40682B1 (fr) | 2014-03-31 | 2015-03-30 | Anticorps anti-ox40 et procédés d'utilisation correspondants |
MA051552A MA51552A (fr) | 2014-03-31 | 2015-03-30 | Anticorps anti-ox40 et procédés d'utilisation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051552A MA51552A (fr) | 2014-03-31 | 2015-03-30 | Anticorps anti-ox40 et procédés d'utilisation |
Country Status (29)
Country | Link |
---|---|
EP (2) | EP3126394B1 (fr) |
JP (2) | JP6637439B2 (fr) |
KR (1) | KR20160145624A (fr) |
CN (1) | CN106103486B (fr) |
AU (1) | AU2015241037B2 (fr) |
BR (1) | BR112016022658A2 (fr) |
CA (1) | CA2943262A1 (fr) |
CL (1) | CL2016002462A1 (fr) |
CR (1) | CR20160500A (fr) |
DK (1) | DK3126394T3 (fr) |
EA (1) | EA201691974A1 (fr) |
ES (1) | ES2763898T3 (fr) |
HR (1) | HRP20192285T1 (fr) |
HU (1) | HUE046767T2 (fr) |
IL (1) | IL247898A0 (fr) |
LT (1) | LT3126394T (fr) |
MA (2) | MA40682B1 (fr) |
MX (1) | MX2016012781A (fr) |
PE (2) | PE20211291A1 (fr) |
PH (1) | PH12016501894B1 (fr) |
PL (1) | PL3126394T3 (fr) |
PT (1) | PT3126394T (fr) |
RS (1) | RS59738B1 (fr) |
SG (1) | SG11201607969XA (fr) |
SI (1) | SI3126394T1 (fr) |
TW (1) | TWI680985B (fr) |
UA (1) | UA121112C2 (fr) |
WO (1) | WO2015153513A1 (fr) |
ZA (1) | ZA201606630B (fr) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2085096A3 (fr) | 2002-09-11 | 2009-08-12 | Genentech, Inc. | Nouvelles compositions et procédés pour le traitement de maladies liées au système immunitaire |
KR101855381B1 (ko) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
RS57840B1 (sr) | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
PT3021869T (pt) | 2013-07-16 | 2020-09-10 | Hoffmann La Roche | Métodos de tratamento do cancro com antagonistas da ligação ao eixo pd-1 e inibidores do tigit |
RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
US20160161485A1 (en) | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
CA2966507A1 (fr) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Procede et biomarqueurs permettant de predire l'efficacite et d'evaluer un traitement par l'agoniste ox40 |
MX2017005929A (es) * | 2014-11-06 | 2017-11-20 | Genentech Inc | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. |
CA2984794A1 (fr) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anticorps anti-ox40 et procedes d'utilisation de ceux-ci |
MY188049A (en) | 2015-05-29 | 2021-11-12 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
MX2017014740A (es) * | 2015-06-08 | 2018-08-15 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40. |
TWI747841B (zh) | 2015-09-25 | 2021-12-01 | 美商建南德克公司 | 抗tigit抗體及使用方法 |
CA2992863A1 (fr) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anticorps bispecifiques specifiques d'un recepteur de co-stimulation du tnf |
US10624974B2 (en) | 2015-10-15 | 2020-04-21 | Dingfu Biotarget Co., Ltd. | Anti-OX40 antibody and application thereof |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
CA3007233A1 (fr) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anticorps et leurs methodes d'utilisation |
CA3006963A1 (fr) * | 2015-12-03 | 2017-06-08 | Ludwig Institute For Cancer Research Ltd. | Anticorps anti-ox40 et leurs procedes d'utilisation |
DE102016105069A1 (de) * | 2016-03-18 | 2017-09-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Antivirale Immuntherapie durch Membranrezeptorligation |
AU2017264754A1 (en) | 2016-05-10 | 2018-12-13 | Genentech, Inc. | Methods of decreasing trisulfide bonds during recombinant production of polypeptides |
WO2017220988A1 (fr) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anticorps multispécifiques pour l'immuno-oncologie |
CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
WO2018031490A2 (fr) * | 2016-08-08 | 2018-02-15 | Sorrento Therapeutics, Inc. | Protéines de liaison anti-ox40 |
CN107815465B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018041119A1 (fr) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Animal non humain génétiquement modifié à ox40 humain ou chimérique |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
JP2020504105A (ja) | 2016-12-19 | 2020-02-06 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なtnfrアゴニストおよびその使用 |
US20190375847A1 (en) | 2017-02-15 | 2019-12-12 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
CN108623686A (zh) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
US11603410B2 (en) | 2017-11-01 | 2023-03-14 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
WO2019106605A1 (fr) | 2017-12-01 | 2019-06-06 | Board Of Regents, The University Of Texas System | Polythérapie pour le traitement du cancer |
US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
CN115925943A (zh) | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
WO2019129136A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-pd-l1 et ses applications |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
WO2019129137A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-lag-3 et utilisations associées |
MY195411A (en) * | 2017-12-29 | 2023-01-19 | Ap Biosciences Inc | Monospecific and Bispecific Proteins With Immune Checkpoint Regulation for Cancer Therapy |
CN108218990B (zh) | 2017-12-29 | 2021-03-02 | 南京优迈生物科技有限公司 | 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用 |
CN111393529B (zh) * | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
TW202003555A (zh) | 2018-03-07 | 2020-01-16 | 英商葛蘭素史克智慧財產發展有限公司 | 用於純化重組多肽之方法 |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
EP3774840A1 (fr) | 2018-03-27 | 2021-02-17 | Bristol-Myers Squibb Company | Surveillance en temps réel de la concentration de protéines à l'aide d'un signal ultraviolet |
EP3775184A1 (fr) | 2018-03-29 | 2021-02-17 | F. Hoffmann-La Roche AG | Modulation de l'activité lactogène dans des cellules de mammifères |
US20210171647A1 (en) * | 2018-05-11 | 2021-06-10 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
TWI754157B (zh) | 2018-07-25 | 2022-02-01 | 大陸商信達生物製藥(蘇州)有限公司 | 抗tigit抗體及其用途 |
US20210355229A1 (en) | 2018-09-26 | 2021-11-18 | Jiangsu Hengrui Medicine Co., Ltd. | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |
EP3889180A4 (fr) * | 2018-11-26 | 2023-01-04 | Nanjing GenScript Biotech Co., Ltd. | Anticorps monoclonal humanisé anti-ox40, son procédé de préparation et son utilisation |
EP3904383A4 (fr) * | 2018-12-25 | 2022-08-17 | Hanx Biopharmaceutics, Inc | Anticorps monoclonal anti-ox40 et utilisation associée |
US10442866B1 (en) | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
WO2020172658A1 (fr) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Procédés d'isolement d'une protéine |
JP2022532930A (ja) | 2019-05-23 | 2022-07-20 | ブリストル-マイヤーズ スクイブ カンパニー | 細胞培養培地をモニターする方法 |
EP3976832A1 (fr) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
WO2020243563A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales destinées à être adaptées à une thérapie immuno-oncologique |
CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
CN110172090B (zh) * | 2019-06-03 | 2020-04-03 | 中山标佳生物科技有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
WO2020259667A1 (fr) * | 2019-06-28 | 2020-12-30 | 江苏恒瑞医药股份有限公司 | Utilisation d'une combinaison d'un agoniste de tlr et d'un anticorps anti-ox40 ou d'un fragment de liaison à l'antigène de ceux-ci dans la préparation d'un médicament pour le traitement de tumeurs |
EP4061844A4 (fr) * | 2019-11-21 | 2023-12-06 | Beigene (Beijing) Co., Ltd. | Procédés de traitement du cancer avec un anticorps anti-ox40 en combinaison avec des agents chimiothérapeutiques |
WO2021098777A1 (fr) * | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Procédés de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des inhibiteurs de pi3 kinase delta |
US20230040604A1 (en) | 2019-12-17 | 2023-02-09 | Amgen Inc. | Interleukin-2 in combination with tnf receptor family members for the expansion of t-regulatory cells |
WO2021190582A1 (fr) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | Composition pharmaceutique d'anticorps anti-ox40 et son utilisation |
EP4127153A2 (fr) | 2020-03-26 | 2023-02-08 | Genentech, Inc. | Cellules de mammifère modifiées |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
BR112022020742A2 (pt) * | 2020-04-17 | 2022-12-20 | Hutchison Medipharma Ltd | Anticorpo anti-ox40 e usos do mesmo |
WO2021262783A1 (fr) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Lignées cellulaires résistantes à l'apoptose |
CN116648507A (zh) | 2020-08-28 | 2023-08-25 | 基因泰克公司 | 宿主细胞蛋白的CRISPR/Cas9多重敲除 |
EP4204453A1 (fr) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Signature de localisation cellulaire et immunothérapie |
WO2022076318A1 (fr) | 2020-10-05 | 2022-04-14 | Bristol-Myers Squibb Company | Procédés pour concentrer des protéines |
EP4229085A1 (fr) * | 2020-10-13 | 2023-08-23 | Almirall S.A. | Molécules bispécifiques et procédés de traitement les utilisant |
WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
AU2022217845A1 (en) | 2021-02-04 | 2023-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-tnfr2 antibody and use thereof |
EP4314068A1 (fr) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Anticorps dirigés contre un cdcp1 clivé et leurs utilisations |
CA3215965A1 (fr) | 2021-04-19 | 2022-10-27 | Amy Shen | Cellules mammiferes modifiees |
WO2022246259A1 (fr) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Cellules modifiées pour la production d'un produit recombiné d'intérêt |
CN115403670A (zh) | 2021-05-26 | 2022-11-29 | 安徽瀚海博兴生物技术有限公司 | 抗cd40抗体及其用途 |
CN115611983A (zh) | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
TW202323280A (zh) * | 2021-10-15 | 2023-06-16 | 新加坡商創響私人有限公司 | 包含抗-ox40單株抗體的藥物製劑 |
WO2023173011A1 (fr) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Expression transitoire de protéines thérapeutiques |
WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
WO2024054992A1 (fr) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Procédés de séparation d'agent chélateur |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
EP0368684B2 (fr) | 1988-11-11 | 2004-09-29 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (fr) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
EP1005870B1 (fr) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
RU2154649C2 (ru) | 1994-07-21 | 2000-08-20 | Акцо Нобель Н.В. | Композиции на основе циклических перекисей кетона |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
ES2332984T3 (es) | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
WO1996040210A1 (fr) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Anticorps et fragments d'anticorps inhibant la croissance des tumeurs |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DK0980244T3 (da) | 1997-05-06 | 2003-09-29 | Wyeth Corp | Anvendelse af quinazoline forbindelser til behandling af polycystisk nyresygdom |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2264166B1 (fr) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001025454A2 (fr) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Procede de regulation de la transcription de genes etrangers |
US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
WO2003011878A2 (fr) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
WO2003035835A2 (fr) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Compositions de glycoproteine |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
EP1502603A4 (fr) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
CA2481656A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules dans lesquelles l'activite de la proteine impliquee dans le transport du gdp-fucose est reduite ou perdue |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
WO2003102157A2 (fr) | 2002-06-03 | 2003-12-11 | Genentech, Inc. | Bibliotheques de phages et anticorps synthetiques |
ES2295639T3 (es) * | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
WO2004065416A2 (fr) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Banques de phages anticorps synthetiques |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
CA2542046A1 (fr) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Composition proteique hybride |
CA2542125A1 (fr) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de .alpha.1,6-fucosyltransferase |
SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005053742A1 (fr) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition a base d'anticorps |
ES2527292T3 (es) | 2004-03-31 | 2015-01-22 | Genentech, Inc. | Anticuerpos anti-TGF-beta humanizados |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CA2885854C (fr) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anticorps anti-p-selectine |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2607147C (fr) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
WO2007056441A2 (fr) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
WO2007064919A2 (fr) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Polypeptides de liaison avec des sequences de diversite limitees |
CA2651567A1 (fr) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Polypeptides de liaison a squelettes optimises |
WO2008027236A2 (fr) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Anticorps multispécifiques |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
BRPI0820875B1 (pt) * | 2007-12-14 | 2021-10-19 | Bristol-Myers Squibb Company | Molécula de ligação isolada, anticorpo monoclonal humano, composição, molécula de ácido nucleico, vetor e célula hospedeira |
MX350962B (es) | 2008-01-07 | 2017-09-27 | Amgen Inc | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. |
CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
HUE036813T2 (hu) | 2008-07-08 | 2018-07-30 | Incyte Holdings Corp | 1,2,5-Oxadiazolok mint indolamin-2,3-dioxigenáz inhibitorok |
BRPI0917891A2 (pt) | 2008-08-25 | 2015-11-24 | Amplimmune Inc | antagonistas de pd-1 e métodos de utilização dos mesmos |
LT4209510T (lt) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui |
EP2504028A4 (fr) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Inhibition simultanée de pd-l1/pd-l2 |
EP2399604A1 (fr) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Nouvelle formulation d'anticorps |
-
2015
- 2015-03-30 SI SI201531040T patent/SI3126394T1/sl unknown
- 2015-03-30 KR KR1020167029913A patent/KR20160145624A/ko active Search and Examination
- 2015-03-30 EP EP15716335.3A patent/EP3126394B1/fr active Active
- 2015-03-30 ES ES15716335T patent/ES2763898T3/es active Active
- 2015-03-30 BR BR112016022658A patent/BR112016022658A2/pt not_active Application Discontinuation
- 2015-03-30 MA MA40682A patent/MA40682B1/fr unknown
- 2015-03-30 SG SG11201607969XA patent/SG11201607969XA/en unknown
- 2015-03-30 CA CA2943262A patent/CA2943262A1/fr not_active Abandoned
- 2015-03-30 PL PL15716335T patent/PL3126394T3/pl unknown
- 2015-03-30 AU AU2015241037A patent/AU2015241037B2/en not_active Ceased
- 2015-03-30 EA EA201691974A patent/EA201691974A1/ru unknown
- 2015-03-30 JP JP2016559908A patent/JP6637439B2/ja active Active
- 2015-03-30 LT LTEP15716335.3T patent/LT3126394T/lt unknown
- 2015-03-30 PE PE2020001996A patent/PE20211291A1/es unknown
- 2015-03-30 CR CR20160500A patent/CR20160500A/es unknown
- 2015-03-30 DK DK15716335.3T patent/DK3126394T3/da active
- 2015-03-30 PE PE2016001873A patent/PE20161571A1/es unknown
- 2015-03-30 UA UAA201610812A patent/UA121112C2/uk unknown
- 2015-03-30 EP EP19183548.7A patent/EP3632934A1/fr not_active Withdrawn
- 2015-03-30 MX MX2016012781A patent/MX2016012781A/es active IP Right Grant
- 2015-03-30 RS RS20191656A patent/RS59738B1/sr unknown
- 2015-03-30 CN CN201580015643.6A patent/CN106103486B/zh active Active
- 2015-03-30 MA MA051552A patent/MA51552A/fr unknown
- 2015-03-30 HU HUE15716335A patent/HUE046767T2/hu unknown
- 2015-03-30 WO PCT/US2015/023432 patent/WO2015153513A1/fr active Application Filing
- 2015-03-30 PT PT157163353T patent/PT3126394T/pt unknown
- 2015-03-31 TW TW104110569A patent/TWI680985B/zh active
-
2016
- 2016-09-19 IL IL247898A patent/IL247898A0/en unknown
- 2016-09-23 ZA ZA2016/06630A patent/ZA201606630B/en unknown
- 2016-09-26 PH PH12016501894A patent/PH12016501894B1/en unknown
- 2016-09-29 CL CL2016002462A patent/CL2016002462A1/es unknown
-
2019
- 2019-12-18 HR HRP20192285TT patent/HRP20192285T1/hr unknown
- 2019-12-20 JP JP2019230794A patent/JP2020072678A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
AU2020264349B2 (en) | Anti-PVRIG antibodies and methods of use | |
MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
MA39248B1 (fr) | Anticorps anti-jagged1 et procédés d'utilisation correspondants | |
MA40938A (fr) | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
MA39095A1 (fr) | Anticorps et immunoconjugués anti-cd33 | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
MX2017000419A (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
MA37538A2 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
MA35712B1 (fr) | Anticorps anti-htra1 et leurs procédés d'utilisation | |
MA35898B1 (fr) | Anticorps anti-lrp5 et leurs procédés d'utilisation | |
MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants | |
MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
MA39411A (fr) | Synthèse de l'énantiomère de la progestérone et ses intermédiaires | |
MA39355B2 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
MA38492A1 (fr) | Anticorps et immunoconjugués anti-b7-h4 | |
MA39141A1 (fr) | Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation | |
MA35947B1 (fr) | Anticorps et immunoconjugués anti-lgr5 | |
MA44925A1 (fr) | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |